Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Breast J. 2010 Jul-Aug;16(4):394-403. doi: 10.1111/j.1524-4741.2010.00938.x. Epub 2010 Jun 10.
Breast magnetic resonance imaging (MRI) is increasingly used in the evaluation of breast cancer. The impact of this modality on patient management at a single institution is evaluated in this paper. A retrospective review was performed for 114 breast cancer patients who had breast MRI as part of their diagnostic evaluation. Clinical information, mammograms, breast ultrasounds and MRI scans were reviewed to determine whether the MRI findings led to a change in patient management. Outcomes as the result of breast MRI were stratified as favorable and unfavorable. Ninety-five patients who had complete clinical, radiologic, and pathologic data were identified. The indications for breast MRI included: high risk screening (n = 3), diagnostic evaluation of disease after neo-adjuvant chemotherapy (n = 24) or prior to re-excision (n = 8), extent of in situ ductal, infiltrating ductal or infiltrating lobular disease histology (DCIS n = 3, IDC n = 24, ILC n = 17), identification of unknown primary (n = 2), assessment of contralateral breast (n = 4), recurrence surveillance (n = 5), and other (n = 5). MRI was concordant with clinical findings and other modalities in 70.5% of cases. MRI altered planned clinical management in 28 of 95 patients (29.5%). Management changes were favorable in 21 patients (75%). Diagnostic evaluation of the breast by MRI alters patient management in 30% of cases depending upon the indications. Alteration in patient management is favorable in 75% of cases. Evaluation of the breast by MRI alters the clinical management of nearly one-third of patients. Changes are favorable for the majority of these cases. Patients undergoing evaluation for contralateral disease, invasive lobular carcinoma and assessment of chemotherapeutic response may derive a more meaningful benefit from MRI.
乳腺磁共振成像(MRI)在乳腺癌的评估中应用越来越广泛。本文评估了这种模式对单一机构患者管理的影响。对 114 例接受乳腺 MRI 作为诊断评估一部分的乳腺癌患者进行了回顾性研究。回顾了临床信息、乳房 X 线照片、乳房超声和 MRI 扫描,以确定 MRI 结果是否导致患者管理的改变。MRI 结果的结果分为有利和不利。确定了 95 例具有完整临床、放射学和病理数据的患者。乳腺 MRI 的适应证包括:高危筛查(n = 3)、新辅助化疗后(n = 24)或再次切除前(n = 8)疾病的诊断评估、原位导管癌、浸润性导管癌或浸润性小叶癌组织学的范围(DCIS n = 3、IDC n = 24、ILC n = 17)、未知原发性(n = 2)、对侧乳房的评估(n = 4)、复发监测(n = 5)和其他(n = 5)。MRI 与临床发现和其他模式在 70.5%的病例中一致。MRI 改变了 95 例患者中的 28 例(29.5%)的计划临床管理。21 例(75%)患者的管理变化是有利的。根据适应证,MRI 对乳腺的诊断评估改变了 30%患者的管理。在 75%的病例中,管理变化是有利的。MRI 改变了近三分之一患者的临床管理。对于这些病例中的大多数,变化是有利的。接受对侧疾病、浸润性小叶癌评估和化疗反应评估的患者可能会从 MRI 中获得更有意义的益处。